Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
90.01
-5.98 (-6.23%)
At close: Jan 8, 2026, 4:00 PM EST
90.00
-0.01 (-0.01%)
After-hours: Jan 8, 2026, 7:45 PM EST
Bright Minds Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts that cover Bright Minds Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $104, which forecasts a 15.54% increase in the stock price over the next year. The lowest target is $80 and the highest is $147.
Price Target: $104 (+15.54%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Bright Minds Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $72 → $147 | Strong Buy | Maintains | $72 → $147 | +63.32% | Jan 7, 2026 |
| BTIG | BTIG | Strong Buy Maintains $72 → $147 | Strong Buy | Maintains | $72 → $147 | +63.32% | Jan 6, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $80 | Strong Buy | Maintains | $80 | -11.12% | Jan 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $115 | Strong Buy | Reiterates | $115 | +27.76% | Dec 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $85 | Strong Buy | Reiterates | $85 | -5.57% | Sep 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.